Sign In
Buy MYGN
$2.86
-2.51 (-46.74%)
At Close: Jul 31, 2026
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
10:01am, Friday, 28'th Mar 2025
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Medical Equipment Stock Jumps on Upgrade
10:40am, Wednesday, 12'th Mar 2025
Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
02:22pm, Tuesday, 25'th Feb 2025
On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics'
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
09:55am, Tuesday, 25'th Feb 2025
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript
08:03pm, Monday, 24'th Feb 2025
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President an
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say
08:00pm, Monday, 24'th Feb 2025
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
07:00pm, Monday, 24'th Feb 2025
Myriad Genetics (MYGN) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.
Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing. Fourth quarter GAAP gross margin of 71.
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
08:30am, Monday, 24'th Feb 2025
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial i
Myriad Genetics Included in Forbes America's Best Employers 2025 List
08:30am, Wednesday, 19'th Feb 2025
SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of Amer
MYGN Stock Might Rise on Collaboration With CancerCARE
10:31am, Tuesday, 11'th Feb 2025
Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
08:30am, Thursday, 06'th Feb 2025
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announ
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
04:15pm, Wednesday, 05'th Feb 2025
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent an
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital patho
Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
08:30am, Wednesday, 29'th Jan 2025
SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at t
